Company Encyclopedia
View More
name
Orient Biotech
688298.SH
Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products worldwide. Its products include POCT instant diagnostic reagents, used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company offers its products for various categories, including COVID-19 diagnosis solutions; immunological diagnosis; quantum-beads flowcytometry; instrument; dry biochemical strips; raw materials; FISH probes; animal health; biochemistry; molecular diagnosis; and quantum-beads multiplex. Zhejiang Orient Gene Biotech Co., Ltd was founded in 2005 and is based in Huzhou, China.
1.595 T
688298.SHMarket value -Rank by Market Cap -/-

Financial Score

10/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking49/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-7.24%D
    • Profit Margin-56.94%E
    • Gross Margin52.85%B
  • Growth ScoreC
    • Revenue YoY2.00%C
    • Net Profit YoY18.36%B
    • Total Assets YoY-8.82%E
    • Net Assets YoY-7.92%D
  • Cash ScoreD
    • Cash Flow Margin-175.62%D
    • OCF YoY2.00%C
  • Operating ScoreE
    • Turnover0.11E
  • Debt ScoreA
    • Gearing Ratio13.52%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Orient Biotech's subsidiary has obtained registration certificates for two medical device products

    Orient Biotech's subsidiary Hangzhou Danwei Biotechnology Co., Ltd. recently obtained registration certificates for two medical device products, namely the 14 types of high-risk HPV nucleic acid detection and 16/18 typing reagent kits, and the combined nucleic acid detection reagent kit for the novel coronavirus and influenza A and B viruses. The registration of these products will enrich the company's product line in the fields of HPV virus detection and respiratory virus detection, helping to expand the domestic market

    Zhitong·
    SH
    688298
    -0.49%
    Zhitong·
    SH
    688298
    -0.49%

    Orient Biotech: Completed the repurchase of 1.8013 million shares

    Orient Biotech announced that the company has completed its share repurchase, with an actual repurchase of 1.8013 million shares, accounting for 0.8935% of the total share capital. The repurchase price range was between RMB 26.45 per share and RMB 29.52 per share, with a total amount of funds used being RMB 49.9943 million. The repurchased shares will be used to maintain the company's value and shareholder rights, and will be sold through centralized bidding trading 12 months after the company discloses the repurchase results and share changes announcement

    Zhitong·
    SH
    688298
    -0.49%
    Zhitong·
    SH
    688298
    -0.49%

    Orient Biotech's subsidiary obtains medical device registration certificate

    Orient Biotech's wholly-owned subsidiary Healgen Scientific LLC and its holding subsidiary Hangzhou Laihe Biotechnology Co., Ltd. recently obtained multiple medical device registration certificates. These products include respiratory combined detection reagents and fully automated biochemical analyzers, which have been certified in China, the European Union, Israel, and Peru, expanding the company's product range in related markets and helping to address the testing of seasonal respiratory infections and other diseases

    Zhitong·
    SH
    688298
    -0.49%
    Zhitong·
    SH
    688298
    -0.49%

    Orient Biotech: Net loss of 163 million yuan in the first half of 2025

    Orient Biotech announced that in the first half of 2025, operating revenue was 403 million yuan, a year-on-year decrease of 3.62%. The net profit attributable to shareholders of the listed company was -163 million yuan, compared to -152 million yuan in the same period last year

    Zhitong·
    SH
    688298
    -0.49%
    Zhitong·
    SH
    688298
    -0.49%

    Institutional Deployment: Structural Opportunities Become Market Consensus

    Recently, A-share listed companies such as Shijia Photons, Orient Biotech, and Mabwell have disclosed the latest information on their top ten shareholders, and the repositioning actions of well-known fund managers have also come to light. At the same time, foreign institutions such as Barclays Bank, UBS, and JP Morgan Securities have frequently increased their holdings in A-shares. The market is expected to reach a critical moment in the second half of 2025, with decision-makers anticipated to strengthen technological self-reliance and boost consumption, while financial policies will remain accommodative. Some industries with improved performance expectations for the semi-annual reports are worth paying attention to

    Zhitong·
    SH
    688313
    +2.13%
    SH
    688298
    -0.49%
    SH
    688062
    -1.37%
    Zhitong·
    SH
    688313
    +2.13%
    SH
    688298
    -0.49%
    SH
    688062
    -1.37%
    © 2025 Longbridge｜Disclaimer